Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from Brokerages

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been given a consensus rating of "Hold" by the nineteen ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.81.

Several brokerages have issued reports on SAGE. Bank of America started coverage on Sage Therapeutics in a report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price target for the company. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Scotiabank decreased their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. Canaccord Genuity Group lowered their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a report on Wednesday, February 12th. Finally, Wedbush restated a "neutral" rating and set a $6.00 price objective on shares of Sage Therapeutics in a report on Wednesday, February 12th.

Sage Therapeutics Stock Performance

SAGE opened at $6.89 on Friday. The firm's fifty day moving average is $7.42 and its two-hundred day moving average is $6.71. The firm has a market cap of $431.46 million, a PE ratio of -1.05 and a beta of 0.20. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $13.47.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The firm had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. During the same period in the prior year, the business earned ($1.80) EPS. The business's revenue for the quarter was up 78.0% compared to the same quarter last year. Equities analysts forecast that Sage Therapeutics will post -3.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

A number of hedge funds have recently bought and sold shares of SAGE. US Bancorp DE grew its stake in shares of Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock worth $67,000 after acquiring an additional 2,268 shares during the period. Teacher Retirement System of Texas grew its position in Sage Therapeutics by 21.6% in the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after purchasing an additional 2,446 shares during the period. Picton Mahoney Asset Management raised its stake in Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 3,581 shares during the last quarter. AlphaQuest LLC bought a new position in shares of Sage Therapeutics during the 1st quarter valued at $32,000. Finally, ProShare Advisors LLC boosted its stake in shares of Sage Therapeutics by 31.2% in the 4th quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company's stock worth $99,000 after buying an additional 4,350 shares during the last quarter. Hedge funds and other institutional investors own 99.22% of the company's stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.